Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Van Andel Research Institute Finding Could Lead to Reduced Side Effects in Anti-Cancer Antibiotics

29.06.2011
Finding could lead to new and improved drugs for several types of cancer

Most of us have had a doctor prescribe an antibiotic for a stubborn bacterial infection, or for a cut that gets infected. However, prescribing an antibiotic to fight cancer? In fact, anti-cancer antibiotics have been used since the 1950s to successfully treat several forms of cancer, but often the side effects limit the duration they can be given to a patient.

One particularly promising anti-cancer antibiotic is Geldanamycin and a modified form of this drug known as 17AAG. Despite its proven ability to selectively kill many different forms of cancer in laboratory studies, the use of these drugs is limited due to side effects, mainly liver failure, in patients.

Newly published results from Van Andel Research Institute (VARI) researchers have determined how the anti-cancer antibiotic Geldanamycin and its derivative 17AAG work in more detail and have uncovered a possible explanation for side effects observed in clinical trials of the drug.

"The article provides novel and significant information about the clinical potential of these compounds in cancer therapy," said Yale School of Medicine Professor and Chair of Pharmacology Joseph Schlessinger, Ph.D.

Although there was much preclinical interest in the antibiotic Geldanamycin as an anti-cancer drug, it turned out to be a poor candidate for clinical trials because of its toxicity. Derivatives such as 17AAG were developed to decrease toxicity and are still being evaluated in clinical trials.

VARI researchers determined how Geldanamycin and 17AAG work in more detail in a study published in Proceedings of the National Academy of Sciences U.S.A., which could inform future drug design, and also found a way to potentially decrease the antibiotics’ toxicity.

“There was so much interest early on in Geldanamycin because it resulted in the degradation of oncoproteins, important protein targets in tumor cells,” said VARI Research Scientist and lead author of the paper Qian Xie, M.D., Ph.D.

“If there is a chance of decreasing the toxicity of Geldanamycin and 17AAG, it would be a boon in the treatment of cancer,” said George Vande Woude, Ph.D., head of the Laboratory of Molecular Oncology at VARI that published the study.

About Van Andel Institute
Established by Jay and Betty Van Andel in 1996, Van Andel Institute (VAI) is an independent research and educational organization based in Grand Rapids, Mich., dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process. Van Andel Education Institute (VAEI) is dedicated to strengthening science education and preparing and motivating individuals to pursue science or science-related professions. Van Andel Research Institute (VARI), the research arm of VAI, is dedicated to probing the genetic, cellular and molecular origins of cancer, Parkinson’s and other diseases and working to translate those findings into effective therapies. This is accomplished through the work of over 200 researchers in 18 on-site laboratories and in collaborative partnerships that span the globe. VARI is affiliated with the Translational Genomics Research Institute, (TGen), of Phoenix, Arizona.

Joe Gavan | EurekAlert!
Further information:
http://www.vai.org

Further reports about: 17AAG Anti-Cancer Antibiotics Geldanamycin VAI anti-cancer antibiotics

More articles from Health and Medicine:

nachricht Penn study identifies new malaria parasites in wild bonobos
21.11.2017 | University of Pennsylvania School of Medicine

nachricht NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures
17.11.2017 | National Institute of Standards and Technology (NIST)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

Previous evidence of water on mars now identified as grainflows

21.11.2017 | Physics and Astronomy

NASA's James Webb Space Telescope completes final cryogenic testing

21.11.2017 | Physics and Astronomy

New catalyst controls activation of a carbon-hydrogen bond

21.11.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>